



JPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Leong Ng

Application No.: 10/618,567

Filed: July 11, 2003

For: ASSAYS AND KITS FOR DETECTING
AND MONITORING HEART DISEASE


Examiner: Not yet known

Art Unit: 1651

Attorney Docket No.: ISA-004.01

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450 on August 31, 2005.



Shirine Darvish

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 23313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97 (b)(3)

Sir:

Applicant hereby brings to the Examiner's attention the references listed on the accompanying form PTO-1449 in compliance with the requirement of 37 C.F.R. §§ 1.56 and 1.97(b)(3). Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

Applicant has listed dates of publication on the attached PTO-1449 for the cited documents based on information presently available to the undersigned. However, the listed publication dates should not be construed that the information in the cited documents was actually published or otherwise publicly available on the date indicated.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that the cited documents are material or constitute "prior art." If the Examiner applies the listed documents as prior art against any claim in the application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the referenced documents be applied against the claims of the present application.

Under 37 C.F.R. § 1.97 (b)(3), this Supplemental Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits; therefore, no fee is believed to be due in connection with this submission. However, the Commissioner is authorized to charge any deficiencies or credit any overpayment to/from our **Deposit Account, No. 06-1448, Reference ISA-004.01.**

Respectfully Submitted,

Date: August 31, 2005

Customer No.: 25181
Patent Group
Foley Hoag LLP
155 Seaport Boulevard
Boston, MA 02210
617-832-1000
617-832-7000 (FAX)


Beth E. Arnold
Reg. No. 35,430
Attorney for Applicant

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>			Docket Number (Optional) ISA-004.01	Application Number 10/618,567		
			Applicant Ng, Leong			
			Filing Date July 11, 2003	Group Art Unit 1651		
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER & TRADEMARK OFFICE	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation
						YES
B3	WO 02/32932	04/25/02	PCT			NO
OTHER DOCUMENTS						<i>(Including Author, Title, Date, Pertinent Pages Etc.)</i>
C24	Douglas et al., "Human Urotensin-II, the Most Potent Mammalian Vasoconstrictor Identified to Date, as a Therapeutic Target for the Management of Cardiovascular Disease, Trends in Cardiovascular Medicine, 10(6):229-237 (2000)					
C25	Ng et al., "Plasma Urotensin in Human Systolic Heart Failure," Circulation 2002, 106: 2877-2880.					
C26	Russell et al., "Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure," Am. J. Physiol. Heart Circ. Physiol. 285:H1576-H1581 (2003)					
C27	Tzanidis et al., "Direct Actions of Urotensin II on the Heart Implications for Cardiac Fibrosis and Hypertrophy," Circulation Research, 93(3):246-253 (2003)					
EXAMINER				DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.						